The cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 and serum soluble triggering receptor expressed on myeloid cells 2 levels can be a biomarker for MOG-AD diagnosis. This evidence concerns the gene MOG and Alzheimer disease.